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Abstract 
Pathological accumulation of abnormally phosphorylated tau protein in astrocytes is a frequent, 
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but poorly characterized feature of the aging brain. Its etiology is uncertain, but its presence is 
sufficiently ubiquitous to merit further characterization and classification, which may stimulate 
clinicopathological studies and research into its pathobiology. This paper aims to harmonize 
evaluation and nomenclature of aging-related tau astrogliopathy (ARTAG), a term that refers 
to a morphological spectrum of astroglial pathology detected by tau immunohistochemistry, 
especially with phosphorylation-dependent and 4R isoform specific antibodies. ARTAG occurs 
mainly, but not exclusively, in individuals over 60 years of age. Tau-immunoreactive astrocytes 
in ARTAG include thorn-shaped astrocytes at the glia limitans and in white matter, as well as 
solitary or clustered astrocytes with perinuclear cytoplasmic tau immunoreactivity that extends 
into the astroglial processes as fine fibrillar or granular immunopositivity, typically in gray 
matter. Various forms of ARTAG may co-exist in the same brain and might reflect different 
pathogenetic processes. Based on morphology and anatomical distribution, ARTAG can be 
distinguished from primary tauopathies but may be concurrent with primary tauopathies or 
other disorders. We recommend four steps for evaluation of ARTAG: 1) identification of five 
types based on the location of either of the two morphologies of tau astrogliopathy: subpial, 
subependymal, gray matter, white matter, perivascular; 2) documentation of the regional 
involvement: medial temporal lobe, lobar (frontal, parietal, occipital, lateral temporal), 
subcortical, brainstem; 3) documentation of the severity of tau astrogliopathy; and 4) 
description of subregional involvement. Some types of ARTAG may underlie neurological 
symptoms; however, the clinical significance of ARTAG is currently uncertain and awaits 
further studies. The goal of this proposal is to raise awareness of astroglial tau pathology in the 
aged brain, facilitating communication among neuropathologists and researchers, and 
informing interpretation of clinical biomarkers and imaging studies that focus on tau-related 
indicators. 
 
Key words: aging; ARTAG; tau astrogliopathy; tau; 
 
 
 
 
 
 
 
 
 
 
Introduction 
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Tau is a microtubule-associated protein that binds to tubulin and promotes its polymerization 
and stabilization into microtubules. Tau isoforms, ranging from 352 to 441 amino acids, are 
generated by the alternative splicing of exons 2, 3, and 10 of the MAPT gene. The six isoforms 
differ from each other by the presence or absence of 29- or 58-amino acid inserts in the N-
terminus domain and by the presence of either three (3R tau isoforms) or four (4R tau isoforms) 
tandem repeat sequences of 31 or 32 amino acids [24]. Mutations in the tau gene (MAPT) can 
cause hereditary frontotemporal dementia and associate with frontotemporal lobar degeneration 
(FTLD) [23, 26, 51, 63].  Following the description of a disorder in one family named ‘multiple 
system tauopathy with presenile dementia’ [62], the term tauopathy was introduced to refer to 
disorders in which tau protein deposition is the predominant feature [23]. Tauopathies are 
characterized by the accumulation of abnormal and hyper-phosphorylated tau protein in the 
brain and are also classified as primary or secondary [32, 37]. Tau pathology is characterized 
as 3R or 4R predominant or mixed 3R+4R type [12, 30, 32]. Primary tauopathies are grouped 
also as FTLD-tau and comprise Pick disease (PiD), progressive supranuclear palsy (PSP), 
corticobasal degeneration (CBD), argyrophilic grain disease (AGD), neurofibrillary tangle 
(NFT) predominant senile dementia (NFT-dementia or “tangle-only” dementia; now included 
in the category of PART, see below), and globular glial tauopathy (GGT) [32, 47]. In addition, 
many other diseases or conditions with diverse etiology, including Alzheimer disease (AD), 
may be associated with tau pathology [32]. The recently introduced term 'primary age-related 
tauopathy' (PART) encompasses neuronal changes previously considered as “normal aging” as 
well as NFT-dementia [14]. PART is distinguished from AD, largely by the absence or scarcity 
of amyloid (Aβ) plaques [14]. In aged individuals sex-dependent tau pathology, developing 
independently from AD has been also described in the hypothalamus [16, 54, 56]. Furthermore, 
chronic traumatic encephalopathy (CTE) is associated with a distinctive pattern of progressive 
neuronal and glial tau pathology [40-42]. 
  
The introduction of the Gallyas silver stain and particularly diagnostic tau 
immunohistochemistry led to the identification of astroglial tau pathology in the aging brain in 
people with or without AD-related changes, cognitive decline or movement disorders [5, 7, 11, 
21, 25, 31, 34-36, 38, 46, 57]. There have been attempts to classify these tau astrogliopathies 
[34], but there is lack of consensus as to how best to describe and categorize them. We 
recommend the term aging-related tau astrogliopathy (ARTAG) to describe the spectrum of 
otherwise unclassified tau immunoreactivity in astrocytes (i.e., distinct from tufted astrocytes, 
astrocytic plaques, ramified astrocytes, or globular astroglial inclusions) mostly in aged 
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individuals detected by tau immunohistochemistry using phosphorylation-specific, 
conformation-specific, or isoform-specific (4R) anti-tau antibodies. Both ARTAG and PART 
affect predominantly the elderly, but PART is characterized by neurofibrillary degeneration 
that is largely restricted to the medial temporal lobe (MTL), basal forebrain, brainstem, and 
olfactory bulb and cortex [14]. PART thus describes neuronal tau pathology, while ARTAG 
focuses on astrocytic tau pathology. Whether PART and ARTAG have separate or shared 
pathogenic pathways is unknown. 
 
We propose a four-step approach for the morphological classification of ARTAG. We 
anticipate that harmonizing the nomenclature and improving consistency in documentation of 
ARTAG is a necessary first step for defining diagnostic guidelines that will result in progress 
in clinicopathological correlation and investigation of the pathogenesis of ARTAG.  
 
Morphology of tau-immunoreactive astrocytes in primary tauopathies and CTE 
The defining lesions of tauopathies are intracellular aggregates of abnormal conformers of tau, 
consistently detectable by immunohistochemistry for phosphoepitopes (e.g., PHF1, CP13, and 
AT8), as well as epitopes to conformational epitopes (e.g., Alz50 and MC1) and tau isoform 
specific epitopes (e.g., 4R tau isoforms) [32]. Regardless of the tauopathy, astroglial tau 
inclusions are mostly 4R tau-immunopositive, although ramified astrocytes in PiD as well as 
occasional protoplasmic astrocytes in PSP may show 3R tau immunoreactivity [21]. Tufted 
astrocytes are characteristic of PSP, and astrocytic plaques are signature lesions of CBD, while 
so-called ramified astrocytes have been described in PiD [15, 32]. In addition, astroglial, 
argyrophilic, and intracytoplasmic flame or thorn-shaped inclusions were described by 
Nishimura et al. in PSP [49]. Phosphorylation-dependent anti-tau antibodies are highly 
sensitive and label lesions that are not consistently detectable by silver impregnation methods, 
but may show variable ubiquitin or p62/sequestosome immunopositivity, such as the globular 
astroglial inclusions (GAI) of GGT [1], or the fine granular tau immunopositivity (some with 
‘bush-like’  appearance) of the astrocytes of AGD [11]. Some of the variation in the morphology 
of the immunolabeled structures was interpreted as representing stages of a process of 
aggregation and fibrillation, analogous to progression from pretangles to neurofibrillary tangles 
in AD [6, 11]. The concept of early-stage tau accumulation in astrocytes has also been discussed 
in relation to the changes in the basal ganglia in PSP [53]. Finally, subpial and subependymal 
clusters of astrocytic tangles have been described in CTE [41]. 
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Overview of astrocytic tau pathologies in the aging brain 
Both neuronal and glial tau pathology increases in frequency with age. The most frequent 
neuronal tau inclusions are neurofibrillary tangles, threads, and argyrophilic grains. Neuronal 
and glial inclusions resembling PSP pathology can be seen in the elderly, even without clinical 
evidence of PSP [17, 18, 34], but these lack the typical multisystem degeneration seen with 
PSP. Furthermore, tuft-shaped astrocytes have been described in a subgroup of elderly 
individuals, especially in association with Lewy body pathology, in a distribution resembling 
that of PSP [25]. Nevertheless, converging data emphasize the presence of a tau astrogliopathy 
that differs from tufted astrocytes or astrocytic plaques as a common finding in the elderly. 
Despite its high prevalence, there is a lack of consensus on whether these astroglial tau 
pathologies in the elderly are clinically relevant, even as a concomitant pathology that might 
lower an individual’s threshold for the development of clinical symptoms. Research in this field 
has been hampered by the variation in staining methods, tau antibodies, and the inconsistent 
nomenclature for astroglial tau pathologies. Importantly, hypertrophic astrocytes, as revealed 
by haematoxylin and eosin staining and immunohistochemistry for glial fibrillary acidic protein 
and excitatory amino acid transporter 2 (EAAT2), are common in the elderly, and presumably 
represent a reaction to multiple types of injury. The location of such reactive astrocytes varies 
considerably among individuals [8, 59]. Colocalization studies have indicated that glial 
fibrillary acidic protein-immunoreactive reactive astrocytes are not necessarily those that are 
also immunoreactive for tau pathology [19].   
 
Ikeda and colleagues were the first to describe tau-positive thorn-shaped astrocytes (TSA), 
which were similar in morphology to tau-positive astrocytes described by Nishimura et al. in 
PSP [49]) in the subpial or subependymal regions of the gray and white matter and frequently 
in the depths of gyri, as well as in the basal forebrain and brainstem, in aged individuals [27-
29]. TSA may occur in multiple conditions [13]. In comparison to the tufted astrocytes of PSP, 
TSA showed more voluminous perinuclear cytoplasm and their processes are often thicker and 
shorter [27]. TSA were only occasionally found in the deep cortical layers. The authors noted 
that anti-ubiquitin antibodies do not label TSA. They interpreted TSA as a non-specific finding 
and found no relationship between the number of TSA and the severity of neurofibrillary 
changes. Argyrophilic, tau-positive subpial and perivascular structures were also described as 
common TSA [27-29].  
 
Schultz et al. reported a high prevalence of TSA in the aged human MTL, particularly the 
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anterior MTL, at the level of the amygdala [57]. TSA were absent in individuals under 60 years, 
but affected almost half of brains from those over 75 years [57]. Indeed, another study also 
failed to find this type of tau astrogliopathy in younger individuals [33]. Schultz et al. [57] 
commented that tau immunopositivity was not confined to the thorn-shaped proximal processes 
of astroglia, but also presented as thread-like processes in the neuropil. They found that 
immunolabeling with AT8 was the most sensitive for demonstrating the TSA, while silver 
staining was less consistent [57]. They also speculated that the preferential subpial and 
perivascular location could be a result of astrocytic reaction to exposure to extravasated plasma 
proteins from the cerebrospinal fluid due to defects in blood-brain barrier permeability 
commonly seen in aging and neurodegeneration [36, 57]. Interestingly, a similar distribution of 
TSA was reported in aged baboons [55]. A study by the MRC-CFAS group confirmed the 
findings of Schultz et al. and added that the TSA could be less commonly observed in the 
vicinity of neuronal cell bodies in gray matter areas such as amygdala and dentate gyrus [36]. 
Also, this study documented the 4R tau nature of TSA [36]. Variable staining for Gallyas and 
p62 suggest that some of these astrocytes accumulate tau in a fibrillar state [34-36, 38, 46]. 
Uchikado et al. also reported that the frequency of TSA increased with age and was independent 
of AGD [66]. All studies agree that the burden of TSA is independent of AD pathology, AGD, 
coiled bodies, dementia status at death, or presence of the APOE ε4 allele [27, 28, 36, 57, 66]. 
These studies, however, were limited to evaluation of the MTL and did not take account of 
cortical and subcortical tau astrogliopathy. Few studies reported tau immunopositivity in glial 
cells in AD cases with prolonged duration of the disease [5, 48, 68]. Finally, a report on NFT-
dementia mentioned the presence of astrocytic tau pathology in white matter and cortex [31]. 
 
The possibility that TSA may have clinical significance was first raised by Munoz and 
colleagues [46]. They used the term ”argyrophilic thorny astrocyte clusters (ATACs)” and 
observed them in the fronto-temporo-parietal cortices and in subcortical white matter in a cohort 
of patients with nonfluent variant of primary progressive aphasia associated with AD pathology 
[46]. Subsequent reports also linked TSA to symptomatology, although not all found an 
association of ATACs with focal neurological syndromes [9, 43]. Munoz and colleagues noted 
ATACs in the white matter without discernible changes in sections stained for myelin. ATACs 
did not show a consistent topographic relationship to amyloid deposits, NFTs, or reactive 
astrogliosis [46]. Interestingly, focal glial tauopathy, interpreted as PSP-type, associated with 
progressive aphasia was reported by Wakabayashi et al. [67]. These observations suggested that 
TSA-like astrocytes might be detected not only in a subependymal or subpial location. 
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A peculiar constellation of tau pathology was documented in a subset of patients with dementia 
[35]. The most characteristic feature was a tau astrogliopathy, which was described as diffuse 
granular tau immunoreactivity in astrocytic processes [35]. The study emphasized additional 
neuronal pathologies, including threads and diffuse neuronal cytoplasmic tau immunoreactivity 
(pretangle-like). A further study distinguished four different patterns based on the anatomical 
distribution of the tau astrogliopathy and its combination with neuronal tau pathology, 
characterized mostly by pretangles and scattered threads [34]: 1) medial temporal lobe type 
(Group I); 2) amygdala type (Group II); 3) limbic-basal ganglia-nigral type with neuronal 
tauopathy (Group III); and 4) hippocampus-dentate gyrus-amygdala type with neuronal 
tauopathy (Group IV). Some of these might represent stages of the same process whereas other 
might be different. Nevertheless, evaluation of tau astrogliopathy in several anatomical regions 
indicated that in some cases astroglial tau pathology in the elderly extends beyond the MTL to 
involve the frontal and parietal cortices, striatum, substantia nigra, and medulla [34]. The 
morphology of tau astrogliopathy in these studies, was reminiscent of that reported by Munoz 
et al. as ATACs [46], although extension of the immunoreactivity into the astrocytic processes 
was emphasized [34, 35]. Distinct accumulation of TSA in the dentate gyrus of the 
hippocampus was also recognized [34, 36]. Mathematical modeling of hippocampal tau 
immunolabeling patterns suggested that some forms of tau astrogliopathy in the elderly involve 
hippocampal subregions in a different pattern from that of primary tauopathies [44]. Ferrer et 
al. [21, 38] showed that the biochemical signature of astroglial tau pathology in the elderly in 
both white and gray matter differed from that of other astrocytic tau pathologies in primary 
tauopathies. Specifically, astroglial tau pathologies in the white matter and gray matter in aging 
brains were not consistently detectable using phospho-specific anti-tau antibody Ser262 or 
conformational tau modifications at amino acids 312 to 322 (MC1), or tau truncated at aspartic 
acid 421 (tau-C3) [21, 38]. 
 
In addition, isolated tufted astrocytes were reported in the occipitotemporal gyrus in an elderly, 
population-representative cohort [36], and a tauopathy with tufted, thorny, fibrous, and 
protoplasmic forms of astrocytic pathology was described by Beach et al. [7], in a series of 
cases with hippocampal sclerosis and also in a community-based study [34]. Sakai et al. [52] 
reported prominent subcortical white matter astrocytic tau pathology in brains from two elderly 
patients in whom CBD was considered. In a study on cervical spondylotic myelopathy, AT8 
immunohistochemistry revealed tau-positive, neuropil threads, astrocytic foot-like perivascular 
or subpial structures, and glial cells with short and thick processes, which the authors termed 
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TSA [58]. Interestingly, prominent tau astrogliopathy may be seen in familial disorders without 
MAPT mutation [20].  
 
In summary, tau-immunoreactive astrogliopathy in the elderly represent a spectrum of 
morphological abnormalities including those originally described as TSA (plump, perinuclear 
cytoplasmic immunoreactivity) and additional fine granular immunoreactivity extending into 
the astrocytic processes in the gray matter. These two morphologies can be present in the same 
brain. TSA may be seen in the subpial, subependymal, or perivascular areas, and in the white 
but also in the gray matter, while the fine granular immunoreactivity is seen in the gray matter. 
Most likely, the different tau-immunoreactive astroglial morphologies in different locations in 
the aging brain, with or without clinical correlation, reflect different pathogenetic events. We 
propose the umbrella term ARTAG to encompass all of these, with or without accompanying 
morphological features of other neurodegenerative disorders, including PSP, CBD, PiD, GGT, 
PART, AD, AGD, and Lewy body pathology. Some clinicopathological studies suggest that 
ARTAG may present clinically with focal symptoms like aphasia when circumscribed to a 
smaller number of regions [46], whereas, in cases with widespread pathology dementia with or 
without parkinsonism might be the clinical presentation [34, 35]; on the other hand, studies 
focusing only on the MTL have found no relationship between ARTAG and cognitive 
impairment or dementia [36].   
 
Differential diagnosis 
We provide the following operational criteria for the six well-defined tau immunoreactive 
astrocytic cytopathologies seen in primary tauopathies and ageing brain as follows (see 
comparison in Table 1 and Fig 1): 
1) Tufted astrocytes: starlike tufts of tau positive radiating fibers. The abnormal densely tau 
immunoreactive tufts are detected in the proximal part of the astrocytic processes, often usually 
in a symmetrical fashion. They are localized to the gray matter (mostly basal ganglia and 
neocortex). 
2) Astrocytic plaques: focal and densely tau immunoreactive stubby dilatations of distal 
processes of astrocytes giving a senile-plaque-like appearance without amyloid core. They are 
localized to the gray matter (mostly basal ganglia and neocortex). 
3) Ramified astrocytes: tau immunoreactivity occupying mostly the perikarya and ramifying 
into the cell processes usually localized to one side of the cell giving the appearance of eccentric 
nuclei of the astrocyte. They are localized to the gray matter and to the white matter in 
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neocortices with severe neuronal loss.  
4) Globular astroglial inclusions: tau immunoreactive distinct globules (up to the size of the 
astroglial nucleus; 1-5 m) and dots (1 m) in the perikarya and proximal parts of astrocytic 
processes, found in gray matter. In contrast to tufted astrocytes and astrocytic plaques, GAI are 
not argyropholic with Gallyas silver stain. 
5) Thorn-shaped astrocytes (TSA): tau immunoreactivity is localized in astrocytic perikarya 
with extension into the proximal parts of the astrocytic processes, with inclusions also in the 
astrocytic endfeet at the glia limitans around blood vessels and at the pial surface. The processes 
are thick and short and reminiscent of thorns. They are localized mostly to the subpial and 
perivascular locations, but also can be found in white matter and less often as clusters in the 
gray matter.  
6) Granular or fuzzy tau immunoreactivity in processes of astrocytes (GFA): fine granular 
immunoreactivity of branching processes with a few dilatations of gray matter astroyctes. The 
perinuclear soma is densely immunoreactive in most of these astrocytes. 
 
The two major cytomorphologies of ARTAG (i.e. TSA and GFA) may accompany tauopathies 
or other neurodegenerative disorders, but ARTAG should be distinguished from the more 
specific astrocytic lesions that are characteristic of primary tauopathies. To understand the 
frequency and relevance of ARTAG it is recommended to document ARTAG as an additional 
feature in primary tauopathies. It must be noted, that the astroglial tau immunoreactivity 
described by Botez et al. in the amygdala of AGD [11] fit best with the granular fine or fuzzy 
tau immunoreactivity in astroglia (GFA) now included as a form of ARTAG. Indeed, astrocytic 
tau pathology is variably seen in AGD [22]. Therefore, it is helpful to comment whether in a 
case of AGD additional ARTAG is present. Furthermore, there are other tau-related disorders 
with astrocytic tau pathology. For instance, astrocytic tau pathology is also a component of 
CTE [40-42]. CTE is associated with a history of repetitive concussive or subconcussive brain 
trauma and is characterized by widespread accumulation of hyperphosphorylated tau in NFTs 
and astrocytes, which have similarity to TSA seen in ARTAG [41]. ARTAG has features that 
overlap those of CTE, including the accentuation of tau pathology around small cerebral vessels 
and in subpial and periventricular areas. On the other hand, tau pathology in CTE is more 
abundant in the depths of the convexity cerebral sulci, especially in early stages [41], an aspect 
that  has not been reported in tau astrogliopathy in the aging brain [29, 34-36, 46, 57]. It is 
possible that CTE pathology has been considered to be age-related astrogliopathy prior to 
recognition of ARTAG, especially for lesions in the MTL, which can be severely affected in 
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more advanced stages of CTE [42]. The characteristic patchy lesions at depths of cerebral sulci 
were not recognized as a specific morphological feature of CTE in earlier studies. Finally, tufted 
astrocytes in PSP, astrocytic plaques in CBD, globular astrocytic inclusions in GGT, and 
ramified astrocytes in PiD are distinct from tau-immunoreactive astrocytes in the gray matter 
in ARTAG (see Table 1).  
 
These observations raise the possibility that ARTAG affects distinct astrocytic populations to 
those in established primary tauopathies. Ikeda and colleagues noted that the distribution of 
TSA was coexistent with prominent subpial and subependymal gliosis [29]. Corpora amylacea, 
which are heavily invested by reactive astrocytes, also share this distribution. Importantly, these 
astroglial populations of the “glia limitans” share common features with fibrous astrocytes, 
which predominate in the white matter and subpial zone [8] and with a subset of astrocytes in 
the gray matter [61], where ARTAG can be also observed. In contrast, astrocytic tau pathologies 
in CBD or PSP involve protoplasmic astrocytes and are independent of reactive astrogliosis 
[19, 65]. A few studies report association of glial fibrillary acidic protein and AT8 
immunoreactivity in subpial but also in gray matter localization of tau astrogliopathy in elderly 
brains [35, 36]. Protoplasmic and fibrous astrocytes differ substantially in their glutamate 
uptake capabilities and capacity and have very different degrees of coupling, which are 
important with regard to their respective calcium wave signals, resting membrane potentials, 
potassium buffering, glutamate metabolism, exchange of second messengers, metabolites, and 
other signaling intermediates between cells [50]. In addition to these differences, reaction of 
astrocytes varies considerably between distinct diseases of the nervous system [60]. It is these 
differences that may be of pathogenetic relevance to the morphologic diversity of 
astrogliopathy in ARTAG. 
 
 
 
 
Evaluation of ARTAG 
Inconsistency in assessing, describing and documenting ARTAG has impeded research and 
limited our understanding of the significance of this pathology. It is not clear whether the 
different patterns of anatomical involvement represent a continuum or distinct abnormalities 
with different causes. Most previous studies have focused on the MTL, but more widespread 
involvement is possible [34, 35]. The relative frequency of ARTAG limited to MTL as opposed 
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to more widespread tau astrogliopathy remains unclear.  Potential etiologies are not known, 
although defective function of the blood-brain barrier [57], metabolic encephalopathy, 
neurodegenerative pathologies, hypoperfusion associated with aging, AD, or vascular dementia 
[39, 64], and even repeated minor trauma with possible genetic risk factors may play a role. 
Clinical, imaging and neuropathological data related to these aspects need to be documented 
precisely to allow a better understanding of the pathogenesis of ARTAG [47]. A method is 
needed to describe morphologies that can be widely accepted and reproducible. As silver 
impregnation methods are difficult to standardize and immunohistochemistry for ubiquitin and 
p62 does not demonstrate all forms of tau cytopathology, optimal characterization of ARTAG 
requires the use of immunohistochemistry for phosphorylated tau. The most widely used 
phosphorylation-dependent anti-tau antibodies that have allowed characterization of ARTAG 
to date include: AT8 (pSer202/Thr205; available from different commercial sources), CP13 
(Ser202; Peter Davies, Litwin-Zucker Research Center for The Study of Alzheimer’s Disease 
and Memory, Manhasset, NY, USA) and PHF-1 or AD2 (Ser396/Ser404; Peter Davies, NY, 
USA for PHF-1 or commercial sources for AD2s). Other antibodies that may prove useful in 
the characterization of ARTAG include those specific for tau phosphorylated at Thr181, 
Ser202, Ser214, Ser396, Ser422, N-terminus region epitope-specific, 4R tau isoform-specific, 
and some conformation-dependent antibodies such as Alz50 (but not MC-1) [21, 35, 38].  
 
Recommendations for sampling and staining are as follows: 
- Preliminary screening for ARTAG should include tau-immunohistochemistry (antibodies 
AT8, CP13, AD2 or PHF-1 are recommended) on two sections representative of the MTL 
(i.e., amygdala and hippocampus at the level of the lateral geniculate body). These regions 
are vulnerable to TSA and GFA. 
- If tau astrogliopathy is noted in the screening section, a systematic characterization of 
ARTAG will require analysis involving additional areas of the frontal, parietal, lateral 
temporal, and occipital cortices, as well as anterior and posterior portion of the basal ganglia, 
thalamus, midbrain at the level of substantia nigra, pons at the level of locus coeruleus, and 
medulla oblongata.  
- In cases where focal cortical symptoms are reported, further cortical areas corresponding to 
the clinical symptoms or signal alterations detected in MRI should also be evaluated. 
 
 15 
ARTAG should be considered when detecting either or both of the two cytomorphologies: TSA 
or GFA. Following this, we propose the following four-step characterization TReSS algorithm 
(Table 2): 
Type? Regional involvement? Severity? Subegional involvement?  
 
 First: Identify the morphologic and distribution types of ARTAG based on parenchymal 
localization of TSA and GFA (note that combination of these types is generally the rule):  
1) Laminar subpial TSA (Fig 2a), or  
2) Subependymal TSA: plump perinuclear cytoplasmic tau immunoreactivity in 
astrocytes in subpial or subependymal locations (Fig 2b). If subpial, it is important to 
note whether this is more pronounced in the sulcal depths in the convexity cerebral 
cortices, as in CTE.  
3) Gray matter GFA (or rarely TSA): solitary (one or two/20x field) (Fig 2c, e) or 
clustered (Fig 2d, f) GFA (three or more/20x field) with fine granular immunopositivity 
of the cytoplasmic processes (GFA), with plump perinuclear cytoplasmic tau 
immunoreactivity.  
4) White matter TSA: astrocytes in the subcortical white matter that show plump 
cytoplasmic immunoreactivity (Fig 2g). Note that in the white matter these usually form 
small clusters (>3 astrocytes) and that it may extend into the adjacent gray matter as 
described for ATAC [46]. 
5) Perivascular TSA: plump cytoplasmic immunoreactivity with tau-immunoreactive 
astrocytic processes around vessels (Fig 2h) in the gray or white matter.  
 
[It must be noted that tau immunohistochemistry occasionally decorates astrocytes at 
the border of chronic traumatic or vascular lesions in young and aged individuals. 
Therefore, this lesion-asssociated tau astrogliopathy is important to document, but is not 
considered an aging related astrogliopathy.] 
 
 
 Second: Identify involvement of gross anatomical regions:  
A) MTL  
B) Lobar 
C) Subcortical  
D) Brainstem  
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[Although the most frequently involved region is the MTL, involvement of further 
regions should be recognized. Moreover, MTL is important for comparison with 
neuroimaging data on MTL atrophy.] 
 
 Third: Document the severity of ARTAG pathology in the region or subregion (see step 
four) examined. ARTAG may appear in focal clusters or in a widespread distribution. We 
propose documentation as to whether ARTAG involves only 1) occasional or 2) numerous 
astrocytes. If the latter, the focal clusters or widespread distribution should be noted. 
Semiquantitative scoring for ARTAG will need to be refined.  
 
 Fourth: Map subregional involvement to promote future exploration and scientific 
discovery related to ARTAG. These are the subdivisions within the gross anatomical 
regions of the second step and include the following (Table 3; examples are shown in Fig 
3):  
- amygdala and hippocampus, inferior temporal gyrus for MTL 
- frontal, parietal, occipital, lateral temporal (middle and superior gyrus) for lobar 
- caudate nucleus, putamen, nucleus accumbens, globus pallidus, thalamus, basal 
forebrain for subcortical 
- mesencephalon, pons, medulla oblongata for brainstem 
 
It should be noted whether ARTAG is associated with features of a particular neurodegenerative 
disorder, or with other disease (cerebrovascular, inflammatory, metabolic, etc.) followed by the 
description of the type and major regional involvement. 
 
Some examples for the diagnostic reporting are provided as follows: 
1) Examples for pure types: 
a. ARTAG subpial type;  
Region: MTL;  
Subregion: hippocampus, inferior temporal cortex;  
Extent: numerous astrocytes and widespread distribution 
b. ARTAG subependymal type;  
Region: Subcortical;  
Subregion: lateral ventricle;  
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Extent: occasional 
 
2) Examples for combinations: 
 a. ARTAG gray matter type;  
Region: MTL and subcortical;  
Subregion: inferior temporal cortex and nucleus accumbens;  
Extent: numerous astrocytes in focal clusters  
plus  
  ARTAG white matter type;  
Region: MTL;  
Subregion: hippocampus, periamygdala white matter, and temporal;  
Extent: numerous astrocytes with widespread distribution; 
 
b. ARTAG perivascular type; 
Region: lobar and subcortical; 
Subregion: frontal cortex and striatum;  
Extent: occasional 
plus 
  ARTAG white matter type;  
Region: MTL and lobar;  
Subregion: lateral temporal, frontal, and parietal lobes;  
Extent: numerous astrocytes in focal clusters. 
 
For example, the cases described by Munoz et al. [46] would be summarized in the diagnostic 
report as: ARTAG gray and white matter type; region: MTL and lobar; extent: numerous in 
focal clusters. For research purposes, the subregional involvement should be added as: gyrus 
ambiens, parahippocampal gyrus, fusiform gyrus, inferior, middle, and superior temporal gyri, 
frontal dorsolateral and orbitofrontal cortices, cingulate gyrus, and inferior parietal lobe. The 
cases described by Kovacs et al. [35] could be summarized as ARTAG gray matter type; region: 
MTL, lobar, subcortical, and brainstem; extent: numerous in focal clusters; plus white matter 
type; region: MTL; extent: numerous and widespread; with further details on the subregional 
involvement. The cases discussed by Santpere and Ferrer [53] as early PSP-like astrocytic 
changes also represent ARTAG with additional features of concomitant PSP-type pathology 
(i.e. cases 4 and 5).  
 18 
 
Summary 
 
ARTAG describes a spectrum of astroglial tau pathologies detected mainly in the elderly 
represented by TSA and GFA, which are distinct from astroglial lesions of primary tauopathies 
(i.e. tufted astrocytes, astrocytic plaques, ramified astrocytes or globular astroglial inclusions). 
The frequency of ARTAG varies depending on the type: subpial, subependymal, and 
perivascular types are more frequent, while gray matter and cerebral white matter types might 
be less common. The etiology of different types might be different; however, all appear mostly 
associated with aging. Although documented in several publications, there is a lack of 
consensus on how ARTAG should be recorded and interpreted. Here we propose steps for a 
systematic characterization with the expectation that this will improve communication about 
and understanding of this condition, including its relation to other brain pathologies and clinical 
symptoms. This approach has the potential to help in several respects: 
1) It will facilitate communication between neuropathologists and 
researchers.  Revisiting and standardizing the terminology should help to move the field 
forward. It will also increase awareness of this pathology, which is under-recognized 
and under-studied. 
2) A better differentiation of ARTAG types may help with assessing their relationship 
to other tauopathies.  This may be particularly important in the context of CTE-related 
tau pathologies. Furthermore, this may help better understanding of differences in the 
pathogenesis of ARTAG types. 
3) A regular system for typing and grading of ARTAG should facilitate comparisons 
between different centers, and the pooling of information in harmonized 
clinicopathological studies. These will potentially pave the way towards mechanistic 
insights and genetic studies into their pathogenesis.   
4) Understanding the nature of ARTAG may help in the interpretation of clinical 
biomarker and imaging studies. 
 
Development of such a common concept (Fig 4) and nomenclature that allows comparisons 
across studies and aggregation of data for large scale multi-institutional analyses is imperative 
in order to understand the phenomena and clinical implications of ARTAG. Future studies 
should also aim to re-evaluate these observations to validate this approach and to develop a 
concise classification of ARTAG for diagnostic neuropathology. To reach this goal, paradigms 
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will be need to be designed for ARTAG along the lines used to standardize evaluation and 
diagnostic criteria for tau, amyloid and α-synuclein and other major pathologies [2-4, 10, 45].  
Subsequently, it will be possible to evaluate inter-rater reliability of the proposed evaluation 
and to eventually merge clinical and pathologic data from multiple centers to determine 
practical significance of ARTAG. At this preliminary stage, however, we limit recommendation 
to a common nomenclature and classification of aging related astrogliopathy and an evaluation 
strategy. 
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Table 1. Operational criteria for the six well-defined tau immunoreactive astrocytic 
cytopathologies seen in primary tauopathies and aging-related tau-astrogliopathy (ARTAG). 
GM: gray matter; WM: white matter; SP: subpial; SE: subependymal; PV: perivascular. In the 
column "Reported” those diseases are mentioned, where there are literature reports of the 
specific astrocytic tau pathologies. PSP: progressive supranuclear palsy; CBD: corticobasal 
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degeneration; PID: Pick disease; GGT: globular glial tauopathy; AGD: argyrophilic grain 
disease. 
 
 
 
 Characteristic immunoreactivity     
  Astrocytic processes     
Name Soma Proximal Distal  Gallyas Reported Location ARTAG 
Tufted astrocytes relatively 
spared 
dense tufts: 
usually 
symmetric 
no + PSP GM no 
Astrocytic plaques spared no stubby 
dilatations 
+ CBD GM no 
Ramified astrocytes dense: 
localized to 
one side 
dense 
ramifications: 
usually 
asymmetric 
no + PID GM,  
WM/GM 
junction 
no 
Globular astroglial 
inclusions 
dense: filled 
with globules 
1-5 m 
globules 
1-2 m 
globules 
- GGT GM no 
Thorn-shaped 
astrocytes (TSA) 
dense: thorn 
or flame 
shaped 
short and thick no +/- with or 
without 
PSP, 
AGD, 
AD, CTE, 
other 
GM, WM, 
SP, SE, 
PV 
yes 
Granular or fuzzy 
astrocytes (GFA) 
dense: 
perinuclear 
accumulation 
fine or fuzzy 
granular  
fine granular - with or 
without 
AGD 
GM yes 
 
 
 
 
Table 2. Evaluation of aging-related tau astrogliopathy (ARTAG). TSA: thorn-shaped 
astrocyte; GFA: granular /fuzzy astrocyte; AP: astrocytic plaque; TA: tufted astrocyte; RA: 
ramified astrocyte; GAI: globular astroglial inclusions. 
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Requires: 
Presence of thorn-shaped astrocytes (TSA) and/or solitary or clustered astrocytes with plump 
cytoplasmic tau immunoreactivity that extend into the astroglial processes as fine granular 
immunopositivity (GFA) distinguishable from AP, TA, RA, and GAI. 
Four-step characterization of ARTAG: 
 Step 1: Distinguish types according to the location: 
  Subpial 
  Subependymal 
  Gray matter 
   White matter 
   Perivascular 
 Step 2: Describe major anatomical distribution  
  Medial temporal lobe 
  Lobar 
  Subcortical 
  Brainstem 
 Step 3: Document the severity of ARTAG  
  Occasional 
  Numerous 
   - Focal 
   - Widespread 
 Step 4: Map subregional involvement and extent (see Table 2) 
Ancillary studies:  
- Description of additional tau pathologies in specific anatomical regions: 
 •       Neurofibrillary degeneration 
 •       Neuropil threads 
 •       Diffuse cytoplasmic neuronal tau immunoreactivity (“pretangles“) 
 •       Dystrophic neurites around or within amyloid plaques 
 •       Oligodendroglial tau immunoreactivity  
- Characterization of tau phosphorylation, conformation, truncation, nitration, ubiquitination, 
immunohistochemistry for 4R and 3R tau; ultrastructural study; genetic studies (MAPT and other 
genes associated with neurodegeneration)  
- Description of concomitant neurodegenerative and non-neurodegenerative pathologies 
- Description of relation to lesions (”perilesional” astrocytic tau immunoreactivity), to corpora 
amylacea, and Rosenthal fibers 
 
 27 
Table 3. Description of aging-related tau astrogliopathy (ARTAG) based on the type and distribution of astrocytic tau pathology. 
MTL: medial temporal lobe; Gy: gyrus; GP: globus pallidus; Caud/Put: Caudate and Putamen; Dent Gyr: dentate gyrus; Medulla obl.: medulla oblongata; Aq: Aqueduct; LV: lateral 
ventricle; 3V: 3rd Ventricle. *: in the case of focal cortical symptoms the anatomical area with clinical relevance should be noted additionally. Combinations of subtypes should be 
expected and described.  
 
Diagnostic screening   
    
Clinicopathological correlation and studies on pathogenesis 
(research) 
STEP 1   STEP 2   STEP 3       STEP 4 
Type 
Major 
anatomical 
involvement 
Severity     Detailed regional distribution and extent of ARTAG 
Subpial 
MTL 
occasional  
or  
numerous 
 (focal/widespread) 
   Inf. Temporal Gy Hippocampus Amygdala   
Lobar     Frontal Parietal Occipital Lateral temporal 
Subcortical     Basal forebrain -  -   
Brainstem     Mesencephalon Pons Medulla obl   
Subependymal 
MTL     Inferior horn       
Lobar     LV: Frontal horn LV:Posterior horn     
Subcortical     LV: Caud 3V: Thalamus      
Brainstem     Aq/Mesencephalon Aq/Pons Aq/Medulla obl.   
Gray matter 
MTL     Inf. Temporal Gy Hippocampus  Amygdala   
Lobar*     Frontal Parietal Occipital Lateral temporal 
Subcortical     Accumbens Caud/Put GP Basal forebrain 
Brainstem     Substantia nigra Pons Medulla obl.   
White matter 
MTL     Inf. Temporal Gy Hippocampus Amygdala   
Lobar*     Frontal Parietal Occipital Lateral temporal 
Subcortical     Internal capsule Subinsular Pencil fibers   
Brainstem     Cerebral pedunculi Pyramids Midline   
Perivascular 
MTL     Inf. Temporal Gy Hippocampus Amygdala   
Lobar     Frontal Parietal Occipital Lateral temporal 
Subcortical     Accumbens Caud/Put GP Basal forebrain 
Brainstem     Mesencephalon Pons Medulla obl.   
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Figure legends 
 
Figure 1. Comparison of tau (here using AT8 antibody) immunoreactivities (IRs) seen in 
primary tauopathies with those observed in aging-related tau astrogliopathy (ARTAG).  
 
Figure 2. Representative photomicrographs of ARTAG types. 
Plump cytoplasmic tau immunoreactivity of astrocytes and tau-positive lining in subpial (a) 
and subependymal (b) location. Gray matter (GM)-type: Single-appearing (c, d) or clusters  (e, 
f) of astrocytes with fine granular tau immunoreactivity in the processes without (c) or with (d) 
plump perinuclear cytoplasmic tau immunoreactivity. White matter (WM)-type: Astrocytes in 
the subcortical white matter with plump cytoplasmic immunoreactivity (g). Perivascular-type: 
Tau-immunoreactive astrocytic processes arranged around vessels (h). 
The bar shown in “a” represents 30 m for a, b, d;  50 m for c, f, g; and 100 m for e, h. 
 
Figure 3. Representative images of different anatomical regions showing ARTAG.  
a: Temporal cortex and white matter (WM); b: Dentate gyrus (Gray matter-type cluster 
enlarged in the right); c: Amygdala; d: Frontal cortex (Gray matter-type single); e: Accumbens 
nucleus (Gray matter-type clusters and single forms); f: Substantia nigra; g and h: medulla 
oblongata (IO: inferior olive; ML: medial lemniscus; n. XII: hypoglossal nucleus). 
The bar shown in “a” represents 150 m for a, b; 100 m for the right inset in b, and c-h. 
 
Figure 4. Summary of the concept of ARTAG. 
Four distinct astroglial tau pathologies are seen in primary tauopathies: tufted astrocytes (TA), 
astrocytic plaques (AP), ramified astrocytes (RA) and globular astroglial inclusions (GAI). 
ARTAG is characterized by two different morphologies: thorn-shaped astrocytes (TSA) and 
fine granular immunoreactivity in astrocytic processes (granular/fuzzy astrocytes: GFA); these 
are seen in the subpial (SP), subependymal (SE), perivascular (PV) areas, and in the white 
(WM) and gray matter (GM).  TSA and GFA may be present in the same brain together. Other 
neurodegenerative diseases (NDDs) may co-exist with ARTAG or with primary tauopathies. 
 
